Related references
Note: Only part of the references are listed.Learning From Animal Models of Obsessive-Compulsive Disorder
Patricia Monteiro et al.
BIOLOGICAL PSYCHIATRY (2016)
The NMDA receptor 'glycine modulatory site' in schizophrenia: D-serine, glycine, and beyond
Darrick T. Balu et al.
CURRENT OPINION IN PHARMACOLOGY (2015)
Chronic intermittent ethanol exposure reduces presynaptic dopamine neurotransmission in the mouse nucleus accumbens
Anushree N. Karkhanis et al.
DRUG AND ALCOHOL DEPENDENCE (2015)
Neonatal quinpirole treatment produces prepulse inhibition deficits in adult male and female rats
Amanda M. Maple et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2015)
Stimulant use disorders in people with psychosis: A meta-analysis of rate and factors affecting variation
Grant E. Sara et al.
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY (2015)
Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment
Golam M. Khandaker et al.
LANCET PSYCHIATRY (2015)
The influence of aripiprazole, olanzapine and enriched environment on depressant-like behavior, spatial memory dysfunction and hippocampal level of BDNF in prenatally stressed rats
Elzbieta Nowakowska et al.
PHARMACOLOGICAL REPORTS (2014)
Glutamate receptor 1 phosphorylation at serine 845 contributes to the therapeutic effect of olanzapine on schizophrenia-like cognitive impairments
Chen Zhang et al.
SCHIZOPHRENIA RESEARCH (2014)
Translating the N-methyl-D-aspartate receptor antagonist model of schizophrenia to treatments for cognitive impairment in schizophrenia
Herbert Y. Meltzer et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2013)
Comorbid substance use disorder in schizophrenia: A selective overview of neurobiological and cognitive underpinnings
Patrizia Thoma et al.
PSYCHIATRY AND CLINICAL NEUROSCIENCES (2013)
Schizophrenia and Substance Abuse Comorbidity: Nicotine Addiction and the Neonatal Quinpirole Model
Russell W. Brown et al.
DEVELOPMENTAL NEUROSCIENCE (2012)
Neonatal 6-Hydroxydopamine Lesioning Enhances Quinpirole-Induced Vertical Jumping in Rats that were Quinpirole Primed During Postnatal Ontogeny
Richard M. Kostrzewa et al.
NEUROTOXICITY RESEARCH (2012)
Lack of association between the regulator of G-protein signaling 4 (RGS4) rs951436 polymorphism and schizophrenia
Erik G. Jonsson et al.
PSYCHIATRIC GENETICS (2012)
Neonatal Quinpirole Treatment Enhances Locomotor Activation and Dopamine Release in the Nucleus Accumbens Core in Response to Amphetamine Treatment in Adulthood
Zackary A. Cope et al.
SYNAPSE (2010)
Signaling pathways in schizophrenia: emerging targets and therapeutic strategies
Caline S. Karam et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2010)
Reduced serum BDNF levels in patients with chronic schizophrenic disorder in relapse, who were treated with typical or atypical antipsychotics
Emmanouil N. Rizos et al.
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY (2010)
Sex Differences in Nicotine Sensitization and Conditioned Hyperactivity in Adolescent Rats Neonatally Treated With Quinpirole: Role of D2 and D3 Receptor Subtypes
Brianna Sheppard et al.
BEHAVIORAL NEUROSCIENCE (2009)
Expression of RGS4 Splice Variants in Dorsolateral Prefrontal Cortex of Schizophrenic and Bipolar Disorder Patients
Lan Ding et al.
BIOLOGICAL PSYCHIATRY (2009)
RGS17, an Overexpressed Gene in Human Lung and Prostate Cancer, Induces Tumor Cell Proliferation Through the Cyclic AMP-PKA-CREB Pathway
Michael A. James et al.
CANCER RESEARCH (2009)
Neonatal co-lesion by DSP-4 and 5,7-DHT produces adulthood behavioral sensitization to dopamine D-2 receptor agonists
Przemyslaw Nowak et al.
PHARMACOLOGICAL REPORTS (2009)
Nicotine sensitization in adult male and female rats quinpirole-primed as neonates
Marla K. Perna et al.
PSYCHOPHARMACOLOGY (2008)
Ontogenetic quinpirole treatment produces long-lasting decreases in the expression of Rgs9, but increases Rgs17 in the striatum, nucleus accumbens and frontal cortex
Amanda M. Maple et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2007)
Consistent with dopamine supersensitivity, RGS9 expression is diminished in the amphetamine-treated animal model of schizophrenia and in postmortem schizophrenia brain
Philip Seeman et al.
SYNAPSE (2007)
The effects of adulthood olanzapine treatment on cognitive performance and neurotrophic factor content in male and female rats neonatally treated with quinpirole
Stephanie K. Thacker et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2006)
Making the case for a candidate vulnerability gene in schizophrenia: Convergent evidence for regulator of G-protein signaling 4 (RGS4)
Pat Levitt et al.
BIOLOGICAL PSYCHIATRY (2006)
DSP-4 prevents dopamine receptor priming by quinpirole
Przemyslaw Nowak et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2006)
The effects of adulthood nicotine treatment on D2-mediated behavior and neurotrophins of rats neonatally treated with quinpirole
RW Brown et al.
SYNAPSE (2006)
Effect of quinpirole on striatal dopamine release and locomotor activity in nicotine-treated mice
A Tammimäki et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2006)
The effects of eticlopride on Morris water task performance in male and female rats neonatally treated with quinpirole
RW Brown et al.
PSYCHOPHARMACOLOGY (2005)
Predictors of schizophrenia - a review
P Maki et al.
BRITISH MEDICAL BULLETIN (2005)
Adulthood nicotine treatment alleviates behavioural impairments in rats neonatally treated with quinpirole: possible roles of acetylcholine function and neurotrophic factor expression
RW Brown et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2004)
Neonatal quinpirole treatment impairs Morris water task performance in early postweanling rats: Relationship to increases in corticosterone and decreases in neurotrophic factors
RW Brown et al.
BIOLOGICAL PSYCHIATRY (2004)
Dopamine D-2 agonist priming in intact and dopamine-lesioned rats
RM Kostrzewa et al.
NEUROTOXICITY RESEARCH (2004)
Impulse activity of midbrain dopamine neurons modulates drug-seeking behavior
M Marinelli et al.
PSYCHOPHARMACOLOGY (2003)
RGS9 modulates dopamine signaling in the basal ganglia
Z Rahman et al.
NEURON (2003)
Ontogenetic quinpirole treatments fail to prime for D-2 agonist-enhancement of locomotor activity in 6-hydroxydopamine-lesioned rats
R Brus et al.
NEUROTOXICITY RESEARCH (2003)
Association of promoter variants in the α7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia
S Leonard et al.
ARCHIVES OF GENERAL PSYCHIATRY (2002)
Ontogenetic quinpirole treatments produce spatial memory deficits and enhance skilled reaching in adult rats
RW Brown et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2002)
Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: A study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment
JM Crook et al.
AMERICAN JOURNAL OF PSYCHIATRY (2001)
The α7-nicotinic acetylcholine receptor and the pathology of hippocampal interneurons in schizophrenia
R Freedman et al.
JOURNAL OF CHEMICAL NEUROANATOMY (2000)
7-OH-DPAT, unlike quinpirole, does not prime a yawning response in rats
J Oswiecimska et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2000)
Sex differences in dopamine receptors and their relevance to ADHD
SL Andersen et al.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS (2000)
Share Paper
